Month: March 2025

VEON appoints Johan Buse as the Incoming CEO of Banglalink

Written by Customer Service on March 17, 2025. Posted in Public Companies.

Johan BuseJohan Buse, Incoming CEO of BanglalinkDubai and Dhaka, 17 March 2025: VEON Ltd. (Nasdaq: VEON), a global digital operator (“VEON” or the “Group”), today announces that Johan Buse has been appointed as the Chief Executive Officer of Banglalink, VEON’s digital operator in Bangladesh, effective 6th April 2025. Johan joins Banglalink from StarHub in Singapore where he led the Consumer Business Group focusing on strategy and business transformation. Prior to that, Johan has decades of experience in the telecom industry across Europe, Asia and the Middle East. He previously served as the Chief Commercial Officer of Ooredoo Oman and held senior positions at Deutsche Telekom Croatia, AXIS and Singtel. Johan will succeed Erik Aas who has made the decision to move on from Banglalink after nine successful years. Commenting on...

Castellum Announces Pricing of $4.5 Million Public Offering of Common Stock and Warrants

Written by Customer Service on March 17, 2025. Posted in Public Companies.

Castellum Announces Pricing of $4.5 Million Public Offering of Common Stock and WarrantsCastellum, Inc. (the “Company” and “Castellum”) (NYSE-American: CTM) announced the pricing of its previously announced public offering of 4,500,000 Units at a public offering price of $1.00 per Unit. Each unit consists of one share of common stock and one warrant to purchase one share of common stock – www.castellumus.comVIENNA, Va., March 16, 2025 (GLOBE NEWSWIRE) — Castellum, Inc. (the “Company” and “Castellum”) (NYSE-American: CTM), a cybersecurity, electronic warfare, and software services company focused on the federal government, today announced the pricing of its previously announced public offering of 4,500,000 Units at a public offering price of $1.00 per Unit. Each unit consists of one share of common stock and one...

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months

Written by Customer Service on March 16, 2025. Posted in Public Companies.

– Continued favorable safety profile for DYNE-251 – – DELIVER Registrational Expansion Cohort is fully enrolled; data from this cohort planned for late 2025 – – Potential for Biologics License Application submission for U.S. accelerated approval in early 2026 – WALTHAM, Mass., March 16, 2025 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced new long-term clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 demonstrating unprecedented and sustained functional improvement at the selected registrational dose of 20 mg/kg Q4W (approximate PMO dose). The DELIVER trial is evaluating DYNE-251 in individuals with Duchenne muscular...

Qifu Technology Announces Fourth Quarter and Full Year 2024 Unaudited Financial Results and Raises Semi-Annual Dividend

Written by Customer Service on March 16, 2025. Posted in Earnings Releases And Operating Results.

SHANGHAI, China, March 16, 2025 (GLOBE NEWSWIRE) — Qifu Technology, Inc. (NASDAQ: QFIN; HKEx: 3660) (“Qifu Technology” or the “Company”), a leading AI-empowered Credit-Tech platform in China, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2024 and raised semi-annual dividend. Fourth Quarter 2024 Business HighlightsAs of December 31, 2024, our platform has connected 162 financial institutional partners and 261.2 million consumers*1 with potential credit needs, cumulatively, an increase of 11.0% from 235.4 million a year ago. Cumulative users with approved credit lines*2 were 56.9 million as of December 31, 2024, an increase of 11.8% from 50.9 million as of December 31, 2023. Cumulative borrowers with successful drawdown, including repeat borrowers was 34.4 million as of...

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Written by Customer Service on March 15, 2025. Posted in Public Companies.

– The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or greater – SOUTH SAN FRANCISCO, Calif., March 15, 2025 (GLOBE NEWSWIRE) — Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced expanded data in a late-breaking oral presentation from the dose-optimization portion of the REFRαME-O1 trial with luveltamab tazevibulin (luvelta) in patients with platinum resistant ovarian cancer (PROC) at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer®. The SGO Annual Meeting will take place from March 14-17, 2025 in Seattle, Washington. In this study, luvelta demonstrated encouraging antitumor...

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

Written by Customer Service on March 15, 2025. Posted in Public Companies.

Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate an objective response rate (ORR) of ~35% in response-evaluable patients On track to initiate Part 2 of the ongoing DENALI clinical trial in 1H 2025, with registration-intent topline data anticipated by year end 2026 Company also presents preclinical combination data of azenosertib with microtubule inhibitor-based antibody drug conjugates (ADCs) demonstrating synergistic antitumor effects SAN DIEGO, March 15, 2025 (GLOBE NEWSWIRE) — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and...

The Becker Milk Company Limited: Nine Months Financial Results and Regular Dividend

Written by Customer Service on March 14, 2025. Posted in Dividend Reports And Estimates.

TORONTO, March 14, 2025 (GLOBE NEWSWIRE) — The Becker Milk Company Limited (the “Company”) (TSX-BEK.B) is pleased to report the results for the nine months ended January 31, 2025. HIGHLIGHTSTotal revenues for the nine months ended January 31, 2025, were $2,275,266 compared to $2,326,873 for the same period in 2024; The non-GAAP financial measure Net Operating Income for year-to-date Q3 fiscal 2025 was $1,844,195 compared to $1,847,990 in fiscal 2024; Net income for year-to-date Q3 fiscal 2025 was $1.43 per share for the year, compared to $0.13 net loss per share in Q3 fiscal 2024.FINANCIAL HIGHLIGHTS Total revenues for the nine months ended January 31, 2025, fell $51,607 compared to the nine months ended January 31, 2024, a result of reduced finance income. Nine months ended January 31 2025 2024Property revenue $2,148,528 $2,120,481Finance...

Update: CANADA CARBON INC. ANNOUNCES PRIVATE PLACEMENT

Written by Customer Service on March 14, 2025. Posted in Public Companies.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES Toronto, ON, Canada, March 14, 2025 (GLOBE NEWSWIRE) — Canada Carbon Inc. (the “Company“) (TSX-V : CCB) is pleased to announce a non-brokered private placement of up to 35,000,000 units (each, a “Unit”) at a price of $0.02 per Unit for aggregate gross proceeds of up to $700,000 (the “Offering”). Each Unit shall be comprised of one (1) common share in the capital of the Company (each, a “Common Share”) and one (1) common share purchase warrant (each, a “Warrant”). Each Warrant shall entitle the holder thereof to acquire one (1) Common Share at a price of $0.06 per share for a period of 60 months from the date of issuance. All securities...

Cannabix Technologies announces Stock Option Grant and Director Resignation

Written by Customer Service on March 14, 2025. Posted in Public Companies.

VANCOUVER, British Columbia, March 14, 2025 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) reports it is granting 3,375,000 incentive stock options to officers, directors and consultants of the Company, exercisable at $0.54 per share for five years, of which 650,000 will expire in two years and will be subject to vesting provisions. In addition, the Company reports that Thomas Clarke has resigned as a Director of the Company. The Company thanks Mr. Clarke for his contributions and wishes him well in his future endeavours. The Company has engaged InvestorsHub.com Inc. (“InvestorsHub”) for news release dissemination services for a fee of $20,000 USD effective May 14, 2025 until the budget is exhausted. The Company may elect to renew the engagement in the future....

Global Federal Credit Union and First Financial Northwest, Inc. Announce Expected Closing Date for Transaction

Written by Customer Service on March 14, 2025. Posted in Mergers And Acquisitions.

ANCHORAGE, Alaska and RENTON, Wash., March 14, 2025 (GLOBE NEWSWIRE) — Global Federal Credit Union (“Global”) and First Financial Northwest, Inc. (the “Company”) (NASDAQ GS: FFNW), the holding company for First Financial Northwest Bank (the “Bank”), jointly announced today they have set the expected closing date for Global’s acquisition of substantially all of the assets and assumption of substantially all of the liabilities (including deposit liabilities) of the Bank (the “Asset Sale”), on the terms and subject to the conditions of the Purchase and Assumption Agreement, dated as of January 10, 2024, by and among the Company, the Bank and Global (the “Agreement”). The Asset Sale is expected to be completed on April 11, 2025, subject to the satisfaction or waiver of the remaining closing conditions set forth in the Agreement. Following...

Month: March 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals